The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) gefitinib and erlotinib, used in adjuvant chemotherapy, showed significant antitumor activity in lung cancer with EGFR gene mutation (39). Here, EGFR is linked to lung cancer.